Interstitial Lung Disease Induced by Pazopanib Treatment

Shotaro Ide; Noriho Sakamoto; Shintaro Hara; Atsuko Hara; Tomoyuki Kakugawa; Yoichi Nakamura; Yoji Futsuki; Koichi Izumikawa; Yuji Ishimatsu; Katsunori Yanagihara; Hiroshi Mukae

doi:10.2169/internalmedicine.56.7380

CASE REPORTS

Interstitial Lung Disease Induced by Pazopanib Treatment

Shotaro Ide, Noriho Sakamoto, Shintaro Hara, Atsuko Hara, Tomoyuki Kakugawa, Yoichi Nakamura, Yoji Futsuki, Koichi Izumikawa, Yuji Ishimatsu, Katsunori Yanagihara, Hiroshi Mukae

Author information

Shotaro Ide
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Department of Infectious Diseases, Unit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan
Noriho Sakamoto
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Shintaro Hara
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Atsuko Hara
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Tomoyuki Kakugawa
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Yoichi Nakamura
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Yoji Futsuki
Department of Respiratory Medicine, Saiseikai Nagasaki Hospital, Japan
Koichi Izumikawa
Department of Infectious Diseases, Unit of Molecular Microbiology and Immunology, Nagasaki University Graduate School of Biomedical Sciences, Japan
Yuji Ishimatsu
Department of Health Sciences, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan
Katsunori Yanagihara
Department of Laboratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan
Hiroshi Mukae
Department of Respiratory Medicine, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan

Keywords: interstitial pneumonia, pneumonitis, pazopanib, drug-induced interstitial lung disease, molecular target drug

JOURNAL OPEN ACCESS

2017 Volume 56 Issue 1 Pages 79-83

DOI https://doi.org/10.2169/internalmedicine.56.7380

Details

Abstract

Although pneumothorax has been reported to be a major pulmonary adverse event in patients treated with pazopanib, a multikinase inhibitor, drug-induced interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese man who received pazopanib for the treatment of femoral leiomyosarcoma and lung metastasis presented with dyspnea and fatigue. He had mild interstitial pneumonia when pazopanib treatment was initiated. Chest computed tomography revealed progressive bilateral ground-glass opacity (GGO) and traction bronchiectasis. We diagnosed DILD due to pazopanib. The patient's pazopanib treatment was interrupted and a steroid was administered. The symptoms and GGO were improved with treatment. Physicians should be aware of DILD due to pazopanib in patients with pre-existing interstitial lung disease.

Corresponding author

Register with J-STAGE for free!